NCT03632213 is a Phase 2 clinical trial of Losartan in Mucopolysaccharidosis IV A, sponsored by Hospital de Clinicas de Porto Alegre.

Who is sponsoring NCT03632213?

NCT03632213 is sponsored by Hospital de Clinicas de Porto Alegre.

What drugs are being tested in NCT03632213?

Interventions in NCT03632213: Losartan, Placebo.

What condition does NCT03632213 study?

NCT03632213 studies Mucopolysaccharidosis IV A, Mucopolysaccharidosis VI, Mucopolysaccharidoses, MPS IV A, MPS VI, MPS - Mucopolysaccharidosis, Morquio A Syndrome, Morquio Syndrome A, Morquio Syndrome.

Is NCT03632213 still recruiting?

NCT03632213 is currently status unknown. Last updated 19 December 2022.

Last reviewed 2022-12-19 · How we verify

NCT03632213

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VI

Status unknown Phase 2 Last updated 19 December 2022

What this trial tests

Phase 2 trial testing Losartan in Mucopolysaccharidosis IV A in 10 participants. Status unknown.

Timeline

7 November 2018

Primary endpoint
4 May 2023

3 August 2023

Quick facts

Lead sponsor	Hospital de Clinicas de Porto Alegre
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	10
Start date	7 November 2018
Primary completion	4 May 2023
Estimated completion	3 August 2023
Sites	1 location across Brazil

Drugs / interventions tested

Losartan (losartan) — full drug profile →
Placebo

Conditions studied

Mucopolysaccharidosis IV A — all drugs for Mucopolysaccharidosis IV A →
Mucopolysaccharidosis VI — all drugs for Mucopolysaccharidosis VI →
Mucopolysaccharidoses — all drugs for Mucopolysaccharidoses →
MPS IV A — all drugs for MPS IV A →

Sponsor

Hospital de Clinicas de Porto Alegre

Who can join

Adults 10 to 40, any sex, with Mucopolysaccharidosis IV A or Mucopolysaccharidosis VI. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Mucopolysaccharidoses (MPS) are multisystemic diseases with significant clinical overlap between their types, with cardiac problems being among the most commonly observed manifestations and are also among the main causes of mortality in these patients. For some of the cardiovascular manifestations, such as aortic root dilation and valve diseases, there is no effective treatment currently available. Losartan, on the other hand, has been shown to be an effective drug for dilation of the aortic root, at least in animal models. This study aims to evaluate the safety and efficacy of losartan in patients with MPS VI and other mucopolysaccharidoses.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Precision Medicine for Lysosomal Disorders.
Pinto E Vairo F, Rojas Málaga D, Kubaski F, Fischinger Moura de Souza C, et al · · 2020 · cited 15× · PMID 32722587 · DOI 10.3390/biom10081110

Verify or expand the search:

Other trials of Losartan

Trials testing the same drug.

NCT06491940 — Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan · NA · not yet recruiting
NCT06333522 — Losartan Use to Mitigate Arthrofibrosis Following Total Joint Arthroplasty · Phase 4 · withdrawn
NCT06150560 — A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial) · Phase 3 · recruiting
NCT06108063 — Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan · Phase 1, PHASE2 · recruiting
NCT06329050 — The Effects of Losartan on Attention Control: An Eye-tracking Study · NA · recruiting

Other recruiting trials for Mucopolysaccharidosis IV A

Currently open trials in the same condition.

NCT05619900 — Registry of Patients Diagnosed With Lysosomal Storage Diseases · recruiting

Other Hospital de Clinicas de Porto Alegre trials

Trials by the same sponsor.

NCT07469722 — POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure · Phase 2, PHASE3 · not yet recruiting
NCT07264179 — Tracheal Cuff Pressure and Postoperative Complications: A Prospective Observational Study. · not yet recruiting
NCT07052058 — Triple-Blind Randomized Clinical Trial of Tocilizumab vs Placebo: Potential Use of an IL-6 Antagonist as an Adjuvant to · Phase 2 · not yet recruiting
NCT06953128 — General Versus Regional Anesthesia in Peripheral Arterial Surgery · NA · not yet recruiting
NCT06934707 — Meal Frequency and Glycemic Control in Individuals With Type 1 Diabetes · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03632213 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospital de Clinicas de Porto Alegre
Last refreshed: 19 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03632213.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing